DealsJun 4, 2026, 04:52 PM
DNA X Terminates $500M Stock Purchase Agreement with Chardan
AI Summary
DNA X, Inc. announced the termination of its ChEF Purchase Agreement and Registration Rights Agreement with Chardan Capital Markets LLC. The ChEF Agreement, originally entered into on September 29, 2025, committed Chardan to purchase up to $500 million of the company's common stock. Both agreements were terminated effective May 28, 2026, by mutual agreement.
Key Highlights
- DNA X, Inc. and Chardan Capital Markets LLC terminated the ChEF Purchase Agreement and Registration Rights Agreement.
- The ChEF Agreement previously allowed Chardan to purchase up to $500 million of DNA X common stock.
- The termination was effective as of May 28, 2026.
Price Impact
More from SONM